Form 4 for MAZE Maze Therapeutics, Inc.
Accepted 2025-12-31 00:00:00 ET · period of report 2025-12-29 · accession 0002050167-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-31 | 2025-12-29+ | MAZE | Dandekar Atul | CSBO | M - OptEx | $10.42 | +72.5K | 82.9K | +697% | +$755.5K |
| DM | 2025-12-31 | 2025-12-29+ | MAZE | Dandekar Atul | CSBO | S - Sale+OE | $40.56 | -72.5K | 10.5K | -87% | -$2.94M |
| DM | 2025-12-31 | 2025-12-29+ | MAZE | Dandekar Atul | CSBO | M - OptEx | $0.00 | -72.5K | 74.2K | -49% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-30 | M | A | 100 | $10.42 | 10,603 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-29 | S | D | 6,035 | $41.13 | 10,503 | D | — | — | (F4) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.99 to $41.51 per share, inclusive. |
| 3 | Common | Common Stock | 2025-12-29 | S | D | 66,365 | $40.51 | 16,538 | D | — | — | (F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.99 to $40.985 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4. |
| 4 | Common | Common Stock | 2025-12-29 | M | A | 72,400 | $10.42 | 82,903 | D | — | — | (F2) The reported total includes 1,562 shares of the Issuer's Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). |
| 5 | Common | Common Stock | 2025-12-30 | S | D | 100 | $40.36 | 10,503 | D | — | — | |
| 6 | Derivative | Stock Option (Right to Buy) | 2025-12-30 | M | D | 100 | $0.00 | 74,143 | D | $10.42 · — to 2031-04-11 | 100 Common Stock | (F5) The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. |
| 7 | Derivative | Stock Option (Right to Buy) | 2025-12-29 | M | D | 72,400 | $0.00 | 74,243 | D | $10.42 · — to 2031-04-11 | 72,400 Common Stock | (F5) The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. |